Indian journal of anaesthesia · 2026
Role of perioperative ketamine on the incidence of rebound pain after regional nerve block in the adult surgical population: A systematic review and meta-analysis of randomised controlled trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Makkar Jeetinder K, Khurana Bisman Jeet K, Singh Preet Mohinder, Singh Narinder P
Аннотация
BACKGROUND AND AIMS: Ketamine is being proposed for the prevention of rebound pain. This meta-analysis systematically reviews evidence from randomised controlled trials on the efficacy of ketamine (intravenous or perineural) in preventing rebound pain in adults undergoing surgery under regional nerve block.
METHODS: A systematic search for randomised controlled trials evaluating ketamine/esketamine (perineural or intravenous) for preventing rebound pain was conducted across databases up to March 2025. Adults receiving regional nerve block with or without ketamine/esketamine were included. The primary outcome was the incidence of rebound pain. Secondary outcomes included onset time and severity of rebound pain, patient satisfaction, and adverse effects.
RESULTS: Six trials enroling 890 patients were included. Ketamine/esketamine significantly reduced the incidence of rebound pain [odds ratio (OR) 0.43, 95% confidence interval (CI) 0.32 to 0.59; P < 0.00001; I² = 39%]. The intravenous subgroup showed a significant reduction (OR 0.48, 95% CI 0.34 to 0.68; P < 0.00001; I² = 21%). The esketamine-versus-control subgroup also favoured active treatment (OR 0.37, 95% CI 0.22 to 0.64; P = 0.0004; I² = 51%). Hallucinations were significantly more frequent with active treatment (OR 12.73, 95% CI 2.98 to 54.41; P = 0.0006; I² = 0%).
CONCLUSION: Current evidence suggests that intravenous and perineural ketamine/esketamine reduce the incidence of rebound pain after a peripheral regional nerve block.
METHODS: A systematic search for randomised controlled trials evaluating ketamine/esketamine (perineural or intravenous) for preventing rebound pain was conducted across databases up to March 2025. Adults receiving regional nerve block with or without ketamine/esketamine were included. The primary outcome was the incidence of rebound pain. Secondary outcomes included onset time and severity of rebound pain, patient satisfaction, and adverse effects.
RESULTS: Six trials enroling 890 patients were included. Ketamine/esketamine significantly reduced the incidence of rebound pain [odds ratio (OR) 0.43, 95% confidence interval (CI) 0.32 to 0.59; P < 0.00001; I² = 39%]. The intravenous subgroup showed a significant reduction (OR 0.48, 95% CI 0.34 to 0.68; P < 0.00001; I² = 21%). The esketamine-versus-control subgroup also favoured active treatment (OR 0.37, 95% CI 0.22 to 0.64; P = 0.0004; I² = 51%). Hallucinations were significantly more frequent with active treatment (OR 12.73, 95% CI 2.98 to 54.41; P = 0.0006; I² = 0%).
CONCLUSION: Current evidence suggests that intravenous and perineural ketamine/esketamine reduce the incidence of rebound pain after a peripheral regional nerve block.